No services found
No Products found
Margetuximab is an Fc-engineered human/mouse chimeric anti-HER2 monoclonal antibody of isotype IgG1? . Margetuximab targets the same epitope on the HER2 extracellular domain and hass the same activity as trastuzumab. However, margetuximab has a higher affinity for both CD16A variants and a weaker one to the inhibitory CD32B Fc receptor, thereby resulting in more efficient antibody-dependent cell-mediated cytotoxicity (ADCC) and higher efficacy compared to trastuzumab. Margetuximab has been marketed under the trade name Margenza.
There are no reviews yet.
Your email address will not be published. Required fields are marked *
In which application did you use the antibody? *
Did it work in your application? *
Your review *
Save my name, email, and website in this browser for the next time I comment.
Send us a message from the form below
Lab / Company
Your cart is currently empty.